Uncategorized – Page 378

Roche’s Phase III Trial Success with IL-6 Blocker Enspryng Tempered by Modest Outcomes

2 years ago talkbio0Tagged Blocker, disappointment, Enspryng, Expectations, interleukin-6, Myasthenia Gravis, Generalized, Phase 3 Clinical Trials, Roche (company), satralizumab

Roche, IL-6 blocker, Enspryng (satralizumab), Phase III trial, Generalized Myasthenia Gravis (gMG), Disappointment, Expectations

Medicare Partially Covers Weight Loss Drugs Amidst High Price Concerns and Future Negotiation Prospects

2 years ago talkbio0Tagged accessibility, Administration occupational activities, Affordability, Increased, Mediation, Medicare, Obesity drugs, premium, Prices, semaglutide, utilization qualifier, Wegovy

Medicare, Obesity drugs, Wegovy, Semaglutide, Price negotiation, Affordability, Accessibility, Premium increases, Utilization management

EU Approves Novo Nordisk’s Groundbreaking Once-Weekly Basal Insulin Icodec for Adults with Diabetes

2 years ago talkbio0Tagged Awiqli, CHMP, European Medicines Agency, insulin icodec, Nordisk, Once-Weekly Insulin Shot

Novo Nordisk, Once-Weekly Insulin Shot, Awiqli, Insulin Icodec, European Medicines Agency (EMA), CHMP Positive Opinion, Type 1 & Type 2 Diabetes Treatment

Innate Pharma Halts Phase 1b Trial for Peripheral T Cell Lymphoma Treatment Amidst NextCure Layoff Announcement

2 years ago talkbio0Tagged Innate Pharma, NextCure Layoffs, Peripheral T-Cell Lymphoma, Phase 1b Trial Termination

Innate Pharma, Peripheral T Cell Lymphoma, Phase 1b Trial Termination, NextCure Layoffs

Orchard Therapeutics Sets $4.25 Million Price Tag for Leukodystrophy Gene Therapy

2 years ago talkbio0Tagged Grail, Lenmeldy, Leukodystropy, Orchard, Prices

Orchard Therapeutics, Leukodystropy, Gene Therapy, Lenmeldy, $4.25 million US price tag

FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients

2 years ago talkbio0Tagged 12.5 mg, Approved, aprocitentan, aspects of adverse effects, Availability of, Clinical Trials, Combined Modality Therapy, Edema, Endothelin receptor antagonist, Idorsia, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, Liquid substance, Precision - temporal, Recommended dosage, Resistant hypertensive disorder, Retention (Psychology), Second Half of 2024, Tryvio, Uncontrolled hypertension, United States Food and Drug Administration

FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects

Lonza Acquires Roche’s Massive Biologics Production Facility in Vacaville, California for $1.2 Billion

2 years ago talkbio0Tagged Biologics Manufacturing Site, California, Capacity, CDMOs, Contract Development, genentech, Global Biologics Market, Growth, Large-Scale Commercial Mammalian Products, Lonza, manufacturing organizations, Roche (company), utilization qualifier, Vacaville

Lonza, Roche, Genentech, Biologics Manufacturing Site, Vacaville/ California, $1.2 Billion Deal, Large-Scale Commercial Mammalian Products, Expansion Plans ($561 Million), Capacity Utilization, Contract Development and Manufacturing Organizations (CDMOs), Global Biologics Market Growth

Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies

2 years ago talkbio0Tagged Ataxia Telangiectasia Mutated Proteins, Catalio Capital Management, cellular targeting, CEO, CLASRP gene, engagers, financing characteristics, HLA Molecule Profiling, Holdings, Personalized Off-the-Shelf Therapies, Robert Ross, T-Lymphocyte, Third Rock

Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross